Hi Jeff and Cheryl,

 

Your urgent reply on this question would be appreciated.  How are we supposed to do this “can’t live with exercise” when this is a live topic?  To the extent that you do not remove so-called “closed generics” from Package 6, please take this as my notice that I cannot live with that section as written.  And, I believe I am not alone.  Can you please respond and let us know if you are leaving it in Package 6?  The clock you guys wound up is ticking.  Thanks!

 

Best,

Paul

 

 

 

From: McGrady, Paul D. <PMcGrady@taftlaw.com>
Sent: Monday, June 29, 2020 4:41 PM
To: Jeff Neuman <jeff.neuman@comlaude.com>; Cheryl Langdon-Orr <langdonorr@gmail.com>
Cc: gnso-newgtld-wg@icann.org
Subject: Package 6

 

Hi Jeff & Cheryl,

 

I was under the impression that we were going to discuss Closed Generics again, but I see it is Package 6.  Is Closed Generics not on the agenda for upcoming calls?  If it is, how can we be doing the so-called “Can’t live with” exercise when the topic isn’t closed on the calls?    

 

Also, I see that the text indicates that the WG agrees the Board instituted a ban on them in the last round.  That is not what the Board resolution says – and in fact there was much discussion on the calls and chat about how “ban” does not apply.  There were three options:  (1) make a change to non-exclusive access, (2) maintain & defer to the next round, or (3) withdraw. Is there a way to make that section reflect the actual facts before we have to undertake the so-called “can’t live with” exercise? The way it is written now essentially takes the starting position of the part of the WG that wants to censor closed generics and implies everyone agrees with it. That isn’t the case.  

 

Best,

Paul

 

 

Taft /
 
Paul D. McGrady / Partner
Taft Stettinius & Hollister LLP
111 E. Wacker Drive, Suite 2800
Chicago, Illinois 60601-3713
Tel: 312.527.4000 • Fax: 312.754.2354
Direct: 312.836.4094 • Cell: 312.882.5020
www.taftlaw.com / PMcGrady@taftlaw.com

https://dg01.redatatech.com/onprem_image_fetch?cid=1016&ep=747d8606d89086fa31a5cf84abfbbf639bdbcc0bfe6c7140c0138fc9774d641b886b9aa0c6d11683f47057b6d5f3988e94a0818231199c14d6fdfe92692ed886cba1fe3d826783ee9a653dcca5732a24ad509dcbe02154dbdbb9334888f9d0fa00569bb98ef66cc7a9f840bd1c009a2fe2e4bc5a33e46f8dfefceb66aa514cd14acea9811e5318f31cc882393e7f7ee5fa019ab16969286fb371e26039327bf37555b04de9825b7b4f4266189ec80036b325a44d4ffdab50a15507915fc7a1249f04a870881fe14c500c47a61d98b1e86a0d93b9444746b9

Taft Bio

V-Card Icon

Taft vCard


Subscribe to our law updates

 

 

 

To receive regular COVID-19 updates from Taft, subscribe here. For additional resources, visit Taft's COVID-19 Resource Toolkit.

This message may contain information that is attorney-client privileged, attorney work product or otherwise confidential. If you are not an intended recipient, use and disclosure of this message are prohibited. If you received this transmission in error, please notify the sender by reply e-mail and delete the message and any attachments.